IL2 and interstitial lung disease: Impaired lung function is one of the major risk factors for mortality in patients with pSS.20 Among 12 patients in the LD-IL-2 group with ILD, there was a significant improvement in diffusing capacity for carbon monoxide at week 12 (median [IQR],72.4% [70.3%-79.8%]; P = .01) and week 24 (median [IQR], 76.4% [71.9%-80.2%]; P = .003) compared with baseline (median [IQR], 66.8% [61.2%-70.1%]).